3998-90-1

Basic information

• Product Name: Methyl 2-chloro-6-methylpyridine-4-carboxylate
• Synonyms: METHYL 2-CHLORO-6-METHYLISONICOTINATE;METHYL 2-CHLORO-6-METHYLPYRIDINE-4-CARBOXYLATE;2-CHLORO-6-PICOLINE-4-CARBOXYLIC ACID METHYL ESTER;METHYL 2-CHLORO-6-METHYLPYRIDINE-4-CARB&;ETHYL 2-CHLORO-6-METHYLISONICOTINATE;Methyl 2-chloro-6-methylpyridine-4-carboxylate 97%;2-METHOXYL-5-NITROPICOLINE;2-Chloro-6-methylisonicotinic acid methyl ester
• CAS NO: 3998-90-1
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.61
• EINECS: 1308068-626-2
• Product Categories: Pyridine;Pyridines;Boronic Acid;pyridine series;Heterocycle-Pyridine series
• Mol File: 3998-90-1.mol

Chemical Properties

• Melting Point: 58-62 °C(lit.)
• Boiling Point: 124-125 °C7 mm Hg(lit.)
• Flash Point: 117.5 °C
• Appearance: /
• Density: 1.247 g/cm³
• Vapor Pressure: 0.00673mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: -0.19±0.10(Predicted)
• CAS DataBase Reference: Methyl 2-chloro-6-methylpyridine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-chloro-6-methylpyridine-4-carboxylate(3998-90-1)
• EPA Substance Registry System: Methyl 2-chloro-6-methylpyridine-4-carboxylate(3998-90-1)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41-43
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 3998-90-1(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
Methyl 2-chloro-6-methylpyridine-4-carboxylate is used as an intermediate in the synthesis of various pyridine derivatives, which are known for their antitubercular properties. These derivatives are crucial in the development of new drugs to combat tuberculosis, a disease that continues to be a significant global health concern.
2. Used in Chemical Synthesis:
Methyl 2-chloro-6-methylpyridine-4-carboxylate can also be utilized as a building block in the synthesis of other complex organic molecules. Its unique structural features make it a valuable component in the creation of novel compounds with potential applications in various fields, such as materials science, agrochemistry, and pharmaceuticals.

InChI:InChI=1/C8H8ClNO2/c1-5-3-6(8(11)12-2)4-7(9)10-5/h3-4H,1-2H3

Upstream product

• 86454-13-9 2-hydroxy-6-methylpyridine-4-carboxylic acid 
• 98491-78-2 methyl 6-methyl-2-hydroxypyridine-4-carboxylate 
• 67-56-1 methanol 
• 25462-85-5 2-chloro-6-methylpyridine-4-carboxylic acid 
• 186581-53-3 diazomethane 
• 86454-13-9 1,2-dihydro-6-methyl-2-oxo-4-pyridinecarboxylic acid 
• 18619-97-1 3-cyano-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid ethyl ester 
• 26413-58-1 2-chloro-6-methyl-4-pyridinecarbonyl chloride 
• 79-37-8 oxalyl dichloride 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 18619-97-1 ethyl 3-cyano-2-hydroxy-6-methylisonicotinate 

Downstream Products

• 25462-85-5 2-chloro-6-methylpyridine-4-carboxylic acid 
• 16830-24-3 methyl 2-methylisonicotinate 
• 117330-40-2 dimethyl 6,6'-dimethyl-2,2'-bipyridine-4,4'-dicarboxylate 
• 122472-76-8 4-hydroxy-5-methoxy-isophthalaldehyde-bis-(2-methyl-isonicotinoylhydrazone) 
• 101281-47-4 2-methyl-isonicotinic acid-(4-acetylamino-benzylidenehydrazide) 
• 107455-74-3 2-methyl-isonicotinic acid-(4-nitro-benzylidenehydrazide) 
• 101091-68-3 2-methyl-isonicotinic acid vanillylidenehydrazide 
• 101091-50-3 2-methyl-isonicotinic acid-[1-(4-hydroxy-phenyl)-ethylLiDenehydrazide] 
• 101289-92-3 2-methyl-isonicotinic acid-(4-dimethylamino-benzylidenehydrazide) 
• 109017-29-0 2-methyl-isonicotinic acid-(1-[2]furyl-ethylLiDenehydrazide) 
• 101091-51-4 2-methyl-isonicotinic acid-(4-methoxy-benzylidenehydrazide) 
• 107922-67-8 2-methyl-isonicotinic acid-(4-hydroxy-benzylidenehydrazide) 
• 103041-64-1 2-methyl-isonicotinic acid-(1-phenyl-propylidenehydrazide) 
• 101091-22-9 2-methyl-isonicotinic acid-(1-phenyl-ethylLiDenehydrazide) 

Relevant articles and documents

D3h-Symmetric Porphyrin-Based Rigid Macrocyclic Ligands for Multicofacial Multinuclear Complexes in a One-Nanometer-Sized Cavity

The one-step synthesis of D3h-symmetric cyclic porphyrin trimers 1 composed of three 2,2′-[4,4′-bis(methoxycarbonyl)]bipyridyl moieties and three porphyrinatozinc moieties was achieved from a nickel-mediated reductive coupling of meso-5,15-bis(6-chloro-4-methoxycarbonylpyrid-2-yl)porphyrinatozinc. Although cyclic trimers 1 were obtained as a mixture that included other cyclic and acyclic porphyrin oligomers, an extremely specific separation was observed only for cyclic trimers 1 when using columns of silica gel modified with pyrenylethyl, cyanopropyl, and other groups. Structural analysis of cyclic trimers 1 was carried out by means of NMR spectroscopy and X-ray crystallography. Treatment of an η3-allylpalladium complex with a cyclic trimer gave a tris(palladium) complex containing three η3-allylpalladium groups inside the space, which indicated that the bipyridyl moieties inside the ring could work as bidentate metalloligands. Separation anxiety: Chromatography on a cyanopropyl-modified column supplied a cyclic porphyrin trimer efficiently from a mixture of acyclic and cyclic oligomers (see scheme; cod=1,5-cyclooctadiene, bpy=2,2′-bipyridyl). Treatment of an η3-allylpalladium complex with the cyclic trimer gives a tris(palladium) complex, which indicates that the cyclic trimer is a versatile macrocyclic ligand for multicofacial multimetallic complexes.

Synthesis and physico-chemical properties of homoleptic copper(I) complexes with asymmetric ligands as a dssc dye

To develop low-cost and efficient dye-sensitized solar cells (DSSCs), we designed and prepared three homoleptic Cu(I) complexes with asymmetric ligands, M1, M2, and Y3, which have the advantages of heteroleptic-type complexes and compensate for their synthetic challenges. The three copper(I) complexes were characterized by elemental analysis, UV-vis absorption spectroscopy, and electrochemical measurements. Their absorption spectra and orbital energies were evaluated and are discussed in the context of TD-DFT calculations. The complexes have high VOC values (0.48, 0.60, and 0.66 V for M1, M2, and Y3, respectively) which are similar to previously reported copper(I) dyes with symmetric ligands, although their energy conversion efficiencies are relatively low (0.17, 0.64, and 2.66%, respectively).

Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents

A series of fused and functionalized pyridine derivatives were designed, synthesized and tested for their potential antitubercular properties. All these novel compounds were prepared by using multistep methods involving the construction of pyridine ring as a key synthetic step. Some of these compounds were found to be interesting when tested for their antitubercular properties in vitro and one of them appeared as an attractive and potential antitubercular agent.

AROMATIC COMPOUNDS AND METAL COMPLEXES THEREOF

Provided are aromatic compounds and metal complexes thereof which may be useful treating various forms of proliferative diseases, such as cancer. In some instances, the metal complexes thereof are relatively stable, and may be suitable for oral administra

6,6′-Dimethyl-2,2′-bipyridine-4-ester: A pivotal synthon for building tethered bipyridine ligands

We describe an efficient and scalable synthesis of 4-carbomethoxy-6,6′-dimethyl-2,2′-bipyridine starting from easily available substituted 2-halopyridines and based on the application of modified Negishi cross-coupling conditions. This compound is a versatile starting material for the synthesis of 4-functionalized 2,2′-bipyridines bearing halide, alcohol, amine, and other functionalities, suitable for conjugation to biological material (2a-c, 3a-g). The utility of this compound in the construction of more complex architectures was further demonstrated by the synthesis of two bifunctional lanthanide chelators; an open chain ligand based on one 2,2′-bipyridine unit and a cryptand based on three 2,2′-bipyridine units [N2(bpy)3COOMe]. In the field of luminophoric biolabels, the photophysical properties of the corresponding Eu(III) cryptate are reported.

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

MGLUR5 MODULATORS II

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

mGluR5 modulators III

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

MGluR5 modulators IV

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

A convenient synthesis of 6,6′-dimethyl-2,2′-bipyridine-4-ester and its application to the preparation of bifunctional lanthanide chelators

We describe a convenient scalable synthesis of 4-carbomethoxy-6,6′-dimethyl-2,2′-bipyridine based on the application of modified Negishi cross-coupling conditions. The use of this building block in the preparation of a number of dissymmetrically 6,6′-tris